Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Santini

Showing results (1-10 of 601) with videos related to

Pageof 61
Sort By:
ESMO Open|May 14, 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak eraDaniele Santini, Giuseppe Tonini
The New England Journal of Medicine|March 11, 2016
Treatment of Advanced Renal-Cell CarcinomaDaniele Santini, Giuseppe Tonini
International Immunopharmacology|May 3, 2021
ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is moreMarco Stellato, Daniele Santini
Tumori|May 24, 2014
Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanibRaffaele Ratta, Daniele Santini
Expert Opinion on Therapeutic Targets|February 17, 2015
A key opinion leader interview with Prof D Santini: insight into cancer researchClaudia Palmer, Daniele Santini
Chemotherapy|November 24, 2021
Metastatic Renal Cell Carcinoma Classified as Good Risk: The Easiest Choice Has Become the HardestMarco Stellato, Daniele Santini
Current Cancer Drug Targets|December 23, 2009
Target therapy of bone metastases and tumoursMichele Caraglia, Daniele Santini
Women'S Health (London, England)|October 7, 2009
Taxanes in adjuvant chemotherapy for early breast cancerBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|May 14, 2008
Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesiumBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetronGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Pageof 61

Showing results (1-10 of 601) with videos related to

Sort By:
Pageof 61
ESMO Open|May 14, 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak eraDaniele Santini, Giuseppe Tonini
The New England Journal of Medicine|March 11, 2016
Treatment of Advanced Renal-Cell CarcinomaDaniele Santini, Giuseppe Tonini
International Immunopharmacology|May 3, 2021
ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is moreMarco Stellato, Daniele Santini
Tumori|May 24, 2014
Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanibRaffaele Ratta, Daniele Santini
Expert Opinion on Therapeutic Targets|February 17, 2015
A key opinion leader interview with Prof D Santini: insight into cancer researchClaudia Palmer, Daniele Santini
Chemotherapy|November 24, 2021
Metastatic Renal Cell Carcinoma Classified as Good Risk: The Easiest Choice Has Become the HardestMarco Stellato, Daniele Santini
Current Cancer Drug Targets|December 23, 2009
Target therapy of bone metastases and tumoursMichele Caraglia, Daniele Santini
Women'S Health (London, England)|October 7, 2009
Taxanes in adjuvant chemotherapy for early breast cancerBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|May 14, 2008
Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesiumBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetronGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Pageof 61